SCHEMBL3103971

SCHEMBL3103971

Cc1noc(-c2ccc(C(=O)N3CCC(C(=O)NC4Cc5ccccc5C4)(c4ccccc4)CC3)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
SCD5 Q86SK9 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
PRMT5 O14744 3/20 0.39
TBK1 Q9UHD2 1/20 0.38
TACR3 P29371 2/20 0.37
ALDH1A1 P00352 3/20 0.37
MGLL Q99685 2/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KDM5A P29375 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103979 0.86 TSHR (0.40) TSHRSCD5CA12CA1CA2
SCHEMBL13092265 0.86 TSHR (0.40) TSHRSCD5CA12CA1CA2
SCHEMBL3100093 0.85 TSHR (0.44) TSHRSCD5CA12CA1CA2
SCHEMBL378371 0.84 CA12 (0.47) TSHRSCD5CA12CA1CA2
SCHEMBL379082 0.84 CA12 (0.47) TSHRSCD5CA12CA1CA2
SCHEMBL13092253 0.82 TSHR (0.44) TSHRSCD5CA12CA1CA2
SCHEMBL378915 0.82 TSHR (0.43) TSHRSCD5CA12CA1CA2
SCHEMBL13092311 0.82 TSHR (0.43) TSHRSCD5CA12CA1CA2
SCHEMBL378032 0.82 TSHR (0.41) TSHRSCD5CA12CA1CA2
SCHEMBL13092256 0.81 TSHR (0.44) TSHRSCD5CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TSHR 895/4885SCD5 4082/4885CA12 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.